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INTRODUCTION
 Pruritus is one of the biggest problems in hemo-
dialysis patients. Unfortunately, approximately 37-
90% of the patients with ESRD suffer from itching.1,2 
Pathophysiology of pruritus in patients with chron-
ic renal failure (CRF) is unknown.3,4 Uremic pruri-
tus usually appears before starting the treatment 
with hemodialysis and gradually progresses.5,6
 Given the various causes of pruritus in 
hemodialysis patients, several treatments have 
been used and investigated.7,8 Few studies have 
been done on the effectiveness of gabapentin with 
antihistamines such ketotifen.9,10In this study, the 
effects of gabapentin and ketotifen on improving 
uremic pruritus were compared.
1. Dr. Saeid Amirkhanlou, MD.
 Assistant Professor, Nephrologist,
2. Dr. Anna Rashedi, MD.
 Radiologist, Assistant Professor,
3. Dr. Jalal Taherian, MD.
 General Practitioner,




1-5:  Department of Internal Medicine,
 Golestan University of Medical Sciences,
 Gorgan, Golestan, Iran.
 Correspondence:
 Dr. Anna Rashedi, MD.
 E-mail: anna_rashedi@yahoo.com
  * Received for Publication: July 10, 2015
  * 1stRevision Received: July 14, 2015
  * 2ndRevision Received: October 28, 2015
  * Final Revision Accepted: November 5, 2015
Original Article
Comparison of gabapentin and ketotifen in treatment
of uremic pruritus in hemodialysis patients
Saeid Amirkhanlou1, Anna Rashedi2, Jalal Taherian3,
Ali Akbar Hafezi4, Sahar Parsaei5
ABSTRACT
Objectives: Uremic pruritus is a common problem in hemodialysis patients. Several treatments have been 
used for decreasing itching in these patients. Gabapentin and ketotifen are two drugs used for treating 
uremic patients.The aim of this study was to compare gabapentin and ketotifen in treatment of uremic 
pruritus in hemodialysis patients.
Methods: In this double-blind randomized clinical trial, 52 hemodialysis patients with uremic pruritus 
referred to 5azarTeaching Hospital in Gorgan in 2013 were studied. Patients were randomly assigned to 
two groups of 26 subjects (groups G and K). In group G, patients treated with gabapentin capsules 100 mg 
daily for 2 weeks, and in Group K, patients treated with ketotifen 1 mg twice daily for 2 weeks. Before and 
at the end of study, pruritus severity was determined based on Shiratori›s severity scores. Collected data 
were analyzed by SPSS-21 statistical software.
Results: There was no significant different between two groups in the age and sex. After two weeks of 
treatment, severity of pruritus was significantly reduced in both groups (88.4% in group G vs. 76.9% in group 
K). Gabapentin compared with ketotifen had a better effect on improving itching in the age group of 30-60 
years and in males. 5 patients (19.2%) in both groups suffered from drowsiness and dizziness, but no serious 
side effects were observed.
Conclusions: The results showed that gabapentin and ketotifen significantly improved pruritus in 
hemodialysis patients, and no significant difference was observed between two groups.
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Treatment of uremic pruritus in hemodialysis patients
METHODS
 This double-blind randomized clinical trial was 
conducted after approval from the Research Ethics 
Committee of Golestan University of Medical 
Sciences.Of 182 hemodialysis patients referred 
to 5azar Teaching Hospital in Gorgan in 2013, 
52 eligible patients with uremic pruritus were 
selected. All patients undergoing hemodialysis 
were similar in frequency and method (maximum 
duration and frequency of hemodialysis) and 
patients suffering from itchy skin condition (non-
uremic pruritus) were excluded. Patients were 
randomly assigned to two groups of 26 subjects 
(groups G and K). In group G, patients treated with 
gabapentin capsules (Iran Daroo Pharmaceutical 
Co., Tehran, Iran) 100 mg daily for 2 weeks, and 
in Group K, patients treated with ketotifen (Abidi 
Pharmaceutical Co., Tehran, Iran) 1 mg twice daily 
for 2 weeks. The patients and drug distributors 
were not aware of the prescribed medications. For 
matching two groups, before beginning the study, 
serum calcium, phosphorus and hemoglobin 
were reached to above 8 mg/dL, less than 5 mg/
dL and about 11 to 12 gr/dL, respectively, and 
the patient were controlled about anemia and 
hyperparathyroidism.
 Before and at the end of study, pruritus severity 
were determined based on Shiratori›s severity 
scores (0= no itching, 1= minimal, 2= mild, 
3= moderate and 4= severe itching).11 Clinical 
response to treatment was determined as follows: 
(1) Complete response (no itching or minimal 
itching after treatment), (2) Partial response (mild 
or moderate severity of itching after treatment) and 
(3) No response (severe pruritus after treatment). 
Two groups of patients were compared in terms of 
age, gender, response to treatment and medication 
side effects (dizziness, drowsiness, tachycardia 
and palpitations). Collected data were analyzed 
by SPSS-21 statistical software and chi-square (χ2) 
and t tests, Fisher’s exact test and Mann-Whitney 
U test.
RESULTS
 A total of 52 hemodialysis patients with 
uremic pruritus in two groups were treated with 
gabapentin and ketotifen. The mean age of patients 
in group G was 60.2±7.4 years, and in group K 
was 57.6±6.2 years, which was not statistically 
significant (P=0.127). In group G, 12 patients 
(46.2%) were males and 14 patients (53.8%) were 
females, and in group K, 13 patients (50%) were 
males and 13 patients (50%) were females, which 
was not significantly different (P=0.098).  
 The results showed that of 52 patients, 49 patients 
(94.2%) reported itching during the day and 47 
patients (90.4%) at night. In group G, 3 patients 
(11.5%) did not respond to treatment, 9 patients 
(34.6%) had a partial response and 14 patients 
(53.8%) had a complete response to treatment. 
In group K, 6 patients (23.1%) did not respond to 
treatment, 7 patients (26.9%) had a partial response 
and 13 patients (50.0%) had a complete response 
to treatment. Hence, there was no significant 
difference between two groups in terms of the 
response to treatment (P=0.481) (Fig.1).
 Comparing the effects of gabapentin and 
ketotifen in the treatment of uremic pruritus by 
age showed that in the age group of 30-60 years, a 
significant difference was observed between two 
groups in terms of response to treatment (P= 0.008), 
but in other age groups, There were no significant 
differences (P>0.05) (Table-I).
 Comparing two treatment groups by sex showed 
that there was a significant difference in the males 
between two groups in terms of response to 
treatment (P= 0.011), but among the females, There 
was no significant difference (P=0.258) (Table-II).
 Assessment of the side effects in both treatment 
groups showed that in both groups, 4 patients 
(15.4%) experienced drowsiness and 1 patient 
(3.8%) had dizziness after taking gabapentin and 
Ketotifen, that there was no statistically significant 
difference (P=1.00) (Table-III). Also, no cases with 
palpitations and tachycardia were observed.
Fig.1: Comparison of the response to treatment with 
gabapentin and ketotifen in hemodialysis patients with 
uremic pruritus. No (no response), P (Partial response), 
and C (Complete response).
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DISCUSSION
 In this study, the effects of gabapentin and 
ketotifen on treating hemodialysis patients with 
uremic pruritus were studied over a two week 
period. The results showed that  both groups of 
patients significantly responded to treatment though 
the response to treatment was greater in gabapentin 
group (88.4% vs 76.9%), but there was no significant 
difference between two groups. Also, in the age 
group of 30-60 years, a significant difference was 
found between two groups in response to treatment, 
so that patients of gabapentin group showed a 
better response to treatment. Moreover, in males, 
a significant difference was observed between two 
groups in terms of response to treatment, so that 
patients treated with gabapentin respond better to 
treatment. It seems that ketotifen is not superior 
to gabapentin in the treatment of uremic pruritus 
and patient response to treatment with gabapentin 
has been relatively better than ketotifen. But in 
terms of side effects, a small number of patients 
in both groups had drowsiness and dizziness and 
no palpitations and tachycardia were reported. 
Therefore, the use of these drugs in the treatment of 
uremic pruritus showed no serious side effects.
 The studies done by other researchers had 
varying results. Marquez, et al. in their study about 
comparing the efficacy and safety of desloratidine 
(an antihistamine) versus gabapentin showed that 
pruritus was decreased with both treatments but 
There were no differences when comparing the final 
pruritus score with both drugs. Excessive sedation 
was common with gabapentin, while desloratadine 
was well tolerated.12In the present study, 
gabapentin and ketotifen (an antihistamine) were 
significantly improved pruritus in hemodialysis 
patients, although the efficacy of gabapentin was 
slightly better than ketotifen but no significant 
difference was found between two groups in terms 
of the side effects. Rayner, et alby compared the 
effects of gabapentin and pregabalin in reducing 
pruritus. They concluded that gabapentin relieved 
itching in 66% of the patients, while pregabalin 
relieved itching in 81% of the patients. Also, 37% 
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Table-II: Comparison of the effects of gabapentin and ketotifen in the 
treatment of uremic pruritus in hemodialysis patients by sex.
Sex Response to Treatment Total P value
 No Partial Complete
  Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Male G 1 1.9 4 7.7 8 15.4 13 25.0 0.011
 K 3 5.8 3 5.8 6 11.5 12 23.1 
Female G 2 3.8 5 9.6 6 11.5 13 25.0 0.258
 K 3 5.8 4 7.7 7 13.5 14 26.9
Table-III: Comparison of the side effects of gabapentin and 
ketotifen in hemodialysis patients with uremic pruritus.
Drug Side Effect Drowsiness Dizziness No Side Effect Total P value
  Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Gabapentin  4 7.7 1 1.9 21 40.4 26 50.0 1.00
Ketotifen  4 7.7 1 1.9 21 40.4 26 50.0
Table-I: Comparison of the effects of gabapentin and ketotifen in the treatment 
of uremic pruritus in hemodialysis patients by age.
Age Groups (year) Response to Treatment Total P value
 No Partial Complete
  Frequency Percent Frequency Percent Frequency Percent Frequency Percent
Under 30 G* 1 1.9 0 0 2 3.8 3 5.8 0.659
 K** 2 3.8 1 1.9 3 5.8 6 11.5 
30-60 G 0 0 6 11.5 6 11.5 12 23.1 0.008
 K 3 5.8 2 3.8 6 11.5 11 19.2 
Upper 60 G 2 3.8 3 5.8 6 11.5 11 19.2 0.854
 K 1 1.9 4 7.7 4 7.7 9 17.3
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of patients suffered side effects from gabapentin.9In 
the present study gabapentin improved pruritus 
in 88.4% of the patients. Finally, only 5 patients 
(19.2%) had drowsiness and dizziness, but none 
of the patients had serious side effects. Razeghi, 
et al. in their study on uremic pruritus refractory 
to antihistamines showed that gabapentin is an 
effective agent in treating uremic pruritus and no 
significant correlation was found between age 
and sex with gabapentin effect.13 This study also 
demonstrated the therapeutic effects of gabapentin 
in uremic patients, but in the age group of 30-60 
years and the males, gabapentin relieved pruritus 
in hemodialysis patients more significant than 
ketotifen. Gunal, et alin their study showed that 
the severity of pruritus in patients treated with 
gabapentin significantly decreased more than 
control group. Also, no significant complications 
were observed. Therefore, gabapentin in the 
treatment of uremic pruritus appeared to be safe 
and effective.14 Vila, et al. in their review article 
showed that gabapentin has demonstrated efficacy 
in the treatment of multiple types of itch especially 
in treating patients with uremic patients who are 
unresponsive to standard therapies. All of the 
controlled studies consisted of 4 weeks of active 
treatment, and no patients discontinued gabapentin 
due to adverse events.15In the study of Manenti, 
et al. all patients experienced a rapid subjective 
improvement in pruritus by gabapentin.16
 There are very few studies on the effects of ketotifen 
compared gabapentin in ESRD patients, however, a 
number of studies have shown the beneficial effects 
of ketotifen in the treatment of uremic pruritus. In 
the study of Francos, et al. determined all uremic 
patients treated with ketotifen had significant 
reductions in pruritus at 8 weeks after treatment.17N
oshad&NazariKhanmiri in a study on comparison 
of gabapentin and antihistamins (hydroxyzine) in 
treatment of uremic pruritus showed that reducing 
the severity of pruritus in gabapentin group (group 
G) was significantly higher than hydroxyzine 
group (group A). Itching remained in 10% of the 
patients in group G versus 80% in group A. The side 
effects were 35% in group G versus 50% in group 
A.10Khalili, et al. in their study about effect of three 
antihistamines on uremic pruritus in the patients 
with CRF showed that hydroxyzine (33%) and 
chlorpheniramine (20%) significantly reduced the 
severity of itching in uremic patients, but ketotifen 
(4.5%) was insignificantly decreased pruritus.18 But 
in the present study, ketotifen relieved itching in 
76.9% of patients.
 It is most likely that uraemic pruritus is a mixture of 
both neuropathic and neurogenic itch. Neuropathic 
itch can originate from damage of the nervous system 
located at any point along the afferent pathway. 
Because its pathophysiology of uremic pruritus is 
poorly understood, the treatment of uraemic pruritus 
remains mainly empirical.14Among the various 
drugs used in the treatment of uremic pruritus, 
gabapentin and ketotifen were investigated in this 
study. Although its mechanism of action is not clear, 
gabapentin appears to have an effect on voltage-
dependent calcium-ion channels. By inhibiting 
neuronal calcium influx, it may interrupt the series 
of events that perhaps lead to the pruritic sensation 
in uraemia.19 On the other hand, it seems that 
histamine in combination with other factors plays 
an important role in the pathogenesis of pruritus,20,21 
although this finding has not been established in 
some studies.22,23Ketotifen is also an antiserotonergic 
agent and mast cell stabilizer, have been effective in 
controlling pruritus of some patients.17
CONCLUSION
 The results of this study showed that gabapentin 
and ketotifen significantly improved pruritus 
in hemodialysis patients. Although the effect 
of gabapentin was better than ketotifen but no 
significant difference was observed between two 
groups. Also, in the age group of 30-60 years and in 
males, gabapentin was significantly more effective 
than ketotifen. Taking these drugs had few side 
effects in patients, therefore, this study indicated the 
efficacy and safety of gabapentin and ketotifen in 
the treatment of uremic pruritus, although further 
studies are needed to confirm the results.
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